Accessibility Menu
Surgical Science Sweden Ab (publ) logo

Surgical Science Sweden Ab (publ)(OM) SUS

Market CapSEK 2.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+353%
5 Year-80%
1 Year-44%
1 Month+56%
SEK 54.00
+3.65%
+1.90Today
Surgical Science Sweden Ab (publ) last closing stock price
MetricPriceDate
Last closeSEK 54.002026-08-31
Surgical Science Sweden Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.22%SEK 49.442026-08-24
1 month+56.16%SEK 34.582026-07-31
3 month+60.14%SEK 33.722026-06-02
Year to date+66.15%SEK 32.502025-12-30
1 year-44.04%SEK 96.502025-08-29
3 year-67.11%SEK 164.202023-09-01
5 year-79.93%SEK 269.002021-09-01
Since inception+353.04%SEK 11.502017-06-19

Surgical Science Sweden Ab (publ) Financials at a Glance

Market Cap

SEK 2.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 1.02B

Net Income (TTM)

SEK 93.14M

EPS (TTM)

SEK 1.83

P/E Ratio

28.54

Dividend

SEK 0.00

Beta (Volatility)

1.15 (Average)

Price

SEK 54.00

Volume

873,069

Open

SEK 52.30

Previous Close

SEK 52.10

Daily Range

SEK 51.90 - SEK 54.95

52-Week Range

SEK 23.70 - SEK 98.30

Estimated Earnings Date

Nov 12, 2026

SUS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Surgical Science Sweden Ab (publ)

Surgical Science Sweden AB (publ) specializes in the development and distribution of virtual reality (VR) simulation platforms for training in laparoscopic and endoscopic procedures. The company is recognized for its innovative training systems that enhance surgical education and improve patient outcomes.

Products and Services
  • LapSim training system for surgical technologists and assistants
  • EndoSim, a dedicated endoscopy simulator for comprehensive training
  • TeamSim platform for inter-professional education in surgical simulation
Growth Outlook
  • Revenue of 235 million SEK in Q1 2026, showing strong demand
  • Gross profit margin of 65.8% in Q1 2026, indicating operational efficiency
  • Continued investment in R&D to enhance product offerings and market reach
Financial Highlights
  • Net income of 18.6 million SEK in Q1 2026, reflecting profitability
  • Current ratio of 4.44, demonstrating strong liquidity position
  • Operating income margin of 9.7% in Q1 2026, showcasing effective cost management
Surgical Science Sweden AB has established itself as a leader in the medical simulation industry, focusing on enhancing surgical training through advanced technology. The company's commitment to innovation is evident in its diverse product offerings, which cater to various aspects of surgical education. The recent financial performance highlights a robust growth trajectory, with significant revenue generation and profitability in the latest quarter. The strong liquidity position further supports the company's ability to invest in future growth initiatives. As the demand for effective surgical training solutions continues to rise, Surgical Science is well-positioned to capitalize on emerging opportunities in the healthcare sector.
AI Generated • Aug 11, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

319

CEO

Tom Englund

Website

www.surgical-science.com

Headquarters

Gothenburg, VG 412 50, SE

SUS Financials

Key Financial Metrics (TTM)

Gross Margin

62.24%

Operating Margin

13.77%

Net Income Margin

9.11%

Return on Equity

2.12%

Return on Capital

2.50%

Return on Assets

1.87%

Earnings Yield

3.50%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

SEK 2.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.03M

Volume

873.07K

Avg. Volume

176.68K

Financials (TTM)

Gross Profit

SEK 636.39M

Operating Income

SEK 140.80M

EBITDA

SEK 244.93M

Operating Cash Flow

SEK 149.13M

Capital Expenditure

-SEK 43.08M

Free Cash Flow

SEK 106.05M

Cash & ST Invst.

SEK 658.39M

Total Debt

SEK 2.86M

Surgical Science Sweden Ab (publ) Performance Analysis

Surgical Science Sweden Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 802,540,000118.8%
20232023-12-31SEK 882,853,00010.0%
20242024-12-31SEK 884,087,0000.1%
20252025-12-31SEK 992,344,00012.2%
Surgical Science Sweden Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3026.0%
Q42025-12-312.0%
Q12026-03-31-12.4%
Q22026-06-308.1%
Surgical Science Sweden Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK 3.6982.7%
20232023-12-31SEK 4.5924.4%
20242024-12-31SEK 2.58-43.8%
20252025-12-31SEK 1.31-49.2%
Surgical Science Sweden Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30202.6%
Q42025-12-3162.5%
Q12026-03-31-43.1%
Q22026-06-3010.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 254.52M

+21.7%

Gross Profit

SEK 155.98M

+14.4%

Gross Margin

61.29%

N/A

Market Cap

SEK 2.66BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

SEK 8.39M

N/A

Employees

317

N/A

Net Income

SEK 20.85M

+203.9%

EBITDA

SEK 65.38M

+392.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 658.39M

+7.9%

Total Debt

SEK 2.86M

+73.8%

Accounts Receivable

SEK 209.75M

-26.0%

Inventory

SEK 234.16M

+13.4%

Long Term Debt

SEK 2.86M

+73.8%

Short Term Debt

SEK 0.00

-100.0%

Return on Assets

1.87%

N/A

Return on Invested Capital

3.01%

N/A

Free Cash Flow

SEK 7.35M

+102.6%

Operating Cash Flow

SEK 15.31M

-5.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About SUS

What is the current price of Surgical Science Sweden Ab (publ)?

Surgical Science Sweden Ab (publ) is trading at SEK 54.00 per share.

What is the 52-week range for Surgical Science Sweden Ab (publ)?

Over the past 52 weeks, Surgical Science Sweden Ab (publ) has traded between SEK 23.70 and SEK 98.30.

How much debt does Surgical Science Sweden Ab (publ) have?

As of the most recent reporting period, Surgical Science Sweden Ab (publ) reported total debt of SEK 2.86M.

How much cash does Surgical Science Sweden Ab (publ) have on hand?

Surgical Science Sweden Ab (publ) reported SEK 658.39M in cash and cash equivalents in its most recent financial results.

What is Surgical Science Sweden Ab (publ)’s dividend yield?

Surgical Science Sweden Ab (publ) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services